Garrido A, Brunet S, Calabuig M, et al. Final results of the CETLAM LAM-203 trial fort he treatment of primary AML up tot the age of 70. EHA 2017, abstract S790.
Ibrutinib plus R-CHOP bij jongere patiënt met ‘non-germinal center B-cell’ DLBCL?
jun 2019 | Lymfoom